Johnson & Johnson’s diabetes care unit will shut down its business in the United States and Canada amid increased competition and after failing to find a buyer.
After posting mixed results for its pimavanserin trial in December 2016, Acadia Pharmaceuticals is broadening its research focus from Alzheimer’s disease psychosis to the treatment of hallucinations and delusions associated with dementia-related psychosis.
Mylan received long-awaited U.S. approval for its generic version of rival Teva’s blockbuster multiple sclerosis treatment Copaxone.
Shares of Sarepta Therapeutics recovered from a dip of about 8 percent as investors seem to have rallied behind the company’s Duchenne muscular dystrophy (DMD) drug Exondys 51.
Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder.
The U.S. Attorney’s Office in Chicago charged a former Zacks biotech analyst with securities fraud over allegations of insider trading.
PTC Therapeutics Inc. failed to supply persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, the U.S. Food and Drug Administration said, dealing a blow to the company’s years-long effort to bring the drug to market.
PureTech subsidiary Gelesis is moving closer to filing for regulatory approval of its obesity treatment Gelesis100 after results of the latest study, the company said.
The FDA warned health-care providers to stick to dosing recommendations for Intercept Pharma’s liver disease medicine Ocaliva after 19 patient deaths were reported.
Nabriva Therapeutics’ experimental antibiotic lefamulin for CABP met the main goal of a late-stage study.